What is Disease Progression in Crohn's Disease and how can it be Measured?

J. Panés
DOI: https://doi.org/10.1093/ecco-jcc/jjv082
2015-08-01
Abstract:To advance in the assessment of therapeutic interventions for diseases that progress slowly but that lead ultimately to permanent disability, such as multiple sclerosis, rheumatoid arthritis or Crohn’s disease [CD], it is essential to evaluate the disease-modifying effects of available treatments. It is also necessary to separate these long-term effects from the short-term effects on symptoms that these treatments may afford. This separation of improvement in symptoms from change in primary disease progression can be difficult. In clinical trials, the measure of the effects of a particular therapeutic intervention is commonly done using indices. The majority of indices that have been developed for assessment of CD are measures of the severity of inflammatory activity, including evaluations based on symptoms and biomarkers [Crohn’s Disease Activity Index [CDAI]],1 endoscopy [Crohn’s Endoscopic Index of Severity [CDEIS]],2 or radiology [Magnetic Resonance Index of Activity [MaRIA]].3 Nevertheless, these are not indices reflecting purely inflammatory activity; each of these indices may be influenced by irreversible damage in the absence of active inflammation; for example, CDAI may increase due to bile salt–induced diarrhoea after ileal resection, CDEIS may increase due to presence of scars or fixed stenotic lesions, and MaRIA may increase due to persistent fibrotic thickening of the bowel wall. This may be among the reasons contributing to higher remission and response rates in early CD with the use … Department of Gastroenterology, Hospital Clinic de Barcelona, Villarroel 170, 08036 Barcelona, Spain. Tel.: +34 932275418; e-mail: jpanes{at}clinic.cat
What problem does this paper attempt to address?